Clearmind Medicine (NASDAQ: CMND) secures U.S. patent for MEAI binge behavior regulators
Rhea-AI Filing Summary
Clearmind Medicine Inc. reports that it has been granted U.S. Patent No. 12,350,242, titled “BINGE BEHAVIOR REGULATORS,” by the United States Patent and Trademark Office. The patent covers compositions and methods using the company’s MEAI (5-methoxy-2-aminoindane) molecule to regulate binge behaviors such as excessive drinking, eating, and gambling.
The company states that this patent expands its global intellectual property portfolio to 32 granted patents across nineteen patent families and supports its clinical programs targeting binge-related disorders, including alcohol use disorder, and its lead candidate CMND-100. Clearmind focuses on non-hallucinogenic, second generation neuroplastogen-derived therapeutics for central nervous system conditions.
Positive
- None.
Negative
- None.
Insights
Clearmind adds a targeted U.S. patent around MEAI for binge behaviors.
Clearmind Medicine has obtained U.S. Patent No. 12,350,242 covering MEAI-based compositions and methods aimed at regulating binge behaviors, including excessive drinking, eating, and gambling. Management links this protection to its programs in binge-related disorders such as alcohol use disorder.
The company notes this raises its portfolio to 32 granted patents across nineteen patent families, reinforcing an IP-heavy strategy around non-hallucinogenic neuroplastogen-derived CNS therapies like CMND-100. Stronger patent coverage can help defend potential future products, though commercial outcomes will depend on clinical and regulatory progress described in other filings.
The first two paragraphs of this press release are incorporated by reference into multiple Clearmind shelf and incentive plan registration statements, aligning disclosure about MEAI and binge behavior regulators with existing capital markets documentation. Subsequent SEC filings are expected to provide more detail on clinical and business developments.
Key Figures
Key Terms
neuroplastogens medical
binge behaviors medical
alcohol use disorder medical
intellectual property portfolio financial
forward-looking statements regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Clearmind Medicine (CMND) announce in this Form 6-K?
What does Clearmind’s new U.S. patent cover for CMND?
How large is Clearmind Medicine’s patent portfolio after this grant?
How does the new patent relate to Clearmind’s clinical programs?
What type of company is Clearmind Medicine (CMND)?
How is this Clearmind press release used in SEC registrations?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: June 2026
Commission file number: 001-41557
CLEARMIND MEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Attached hereto and incorporated herein is the Registrant’s press release issued on June 18, 2026, titled “Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators”.
The first two paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
EXHIBIT INDEX
| Exhibit No. | ||
| 99.1 | Press release titled: “Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Clearmind Medicine, Inc. | ||
| (Registrant) | ||
| Date: June 18, 2026 | By: | /s/ Adi Zuloff-Shani |
| Name: | Adi Zuloff-Shani | |
| Title: | Chief Executive Officer | |
3
Exhibit 99.1
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
Vancouver, Canada, June 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced that it has been granted a U.S. Patent, No. 12,350,242, titled “BINGE BEHAVIOR REGULATORS”, by the United States Patent and Trademark Office (USPTO).
The patent, which refers to Clearmind’s molecule MEAI (5-methoxy-2-aminoindane), covers innovative compositions and methods utilizing a pharmaceutically acceptable salt to regulate binge behaviors, including excessive drinking, eating, and gambling.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “We are very pleased to secure this important U.S. patent, increasing our global portfolio to 32 granted patents and reinforcing our leadership in psychedelic-based therapies. We believe that this milestone directly advances our clinical programs for binge-related disorders, such as alcohol use disorder, where patients urgently need more effective options. Clearmind remains committed to expanding its robust intellectual property portfolio. We continue to build broad IP protection in major global markets for our lead candidate, CMND-100, and our broader pipeline of central nervous system (CNS) therapeutic technologies."
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its leadership in psychedelic-based therapies, advancing its clinical programs for binge-related disorders and its commitment to expanding its robust intellectual property portfolio. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.